Zealand Pharma jumps on amylin monotherapy opportunity
** Shares in Danish Zealand Pharma ZELA.CO jump around 10% to a new record high, with an analyst pointing to comments by rival Novo Nordisk that it will take new amylin analogue into development for monotherapy treatment with amylin of obesity
** "Having the world's leading company in obesity, going for amylin as monotherapy, also strongly validates the thesis of amylin monotherapy for weight management," says Nordea analyst Michael Novod
** Amycretin targets a hormone called amylin in the pancreas that affects hunger
** He adds Novo's compelling amycretin data and venture into amylin monotherapy could amplify the appeal of Zealand's similar treatment, petrelintide
** Novod further indicates that this could intensify interest in petrelintide from potential pharma partners, pending positive obesity clinical data
** Including Thursday's rise, the stock has nearly doubled in value so far this year
** Shares are among the best performers on pan-European STOXX 600 index .STOXX, by 1417 GMT jump 10% to a new record high of DKK 749
Reporting by Jesus Calero
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
